Leerink Partnrs Lowers Theravance Biopharma (NASDAQ:TBPH) to Hold

Theravance Biopharma (NASDAQ:TBPH) was downgraded by stock analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports.

Other equities analysts have also issued reports about the company. SVB Leerink lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $15.00 to $10.00 in a research note on Tuesday. HC Wainwright dropped their price target on Theravance Biopharma from $20.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday. StockNews.com downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. BTIG Research initiated coverage on Theravance Biopharma in a research report on Friday, April 12th. They issued a “buy” rating and a $21.00 price objective on the stock. Finally, TD Cowen dropped their price target on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a research report on Tuesday. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $13.75.

Theravance Biopharma Stock Performance

TBPH traded up $0.10 during trading hours on Tuesday, reaching $7.93. The company’s stock had a trading volume of 57,822 shares, compared to its average volume of 386,237. Theravance Biopharma has a 52 week low of $7.69 and a 52 week high of $11.71. The company’s 50-day moving average is $9.05 and its 200-day moving average is $9.09. The firm has a market cap of $385.66 million, a PE ratio of -9.12 and a beta of 0.24.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). Theravance Biopharma had a negative return on equity of 18.97% and a negative net margin of 72.79%. The company had revenue of $14.26 million during the quarter, compared to the consensus estimate of $15.81 million. During the same quarter in the previous year, the business posted ($0.28) EPS. Equities analysts anticipate that Theravance Biopharma will post -0.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now owns 335,965 shares in the company, valued at approximately $3,023,685. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of TBPH. Los Angeles Capital Management LLC purchased a new position in Theravance Biopharma during the second quarter worth about $286,000. Jacobs Levy Equity Management Inc. raised its stake in Theravance Biopharma by 41.6% during the first quarter. Jacobs Levy Equity Management Inc. now owns 557,971 shares of the biopharmaceutical company’s stock worth $5,005,000 after purchasing an additional 163,951 shares during the period. Kennedy Capital Management LLC raised its stake in Theravance Biopharma by 3.7% during the first quarter. Kennedy Capital Management LLC now owns 38,202 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 1,359 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Theravance Biopharma by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 49,475 shares of the biopharmaceutical company’s stock worth $444,000 after purchasing an additional 3,532 shares during the period. Finally, State Board of Administration of Florida Retirement System raised its stake in Theravance Biopharma by 28.2% during the first quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 4,990 shares during the period. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.